My career goal is to put myself out of a job by eradicating ovarian cancer. As the son of two Air Force officers, I had the privilege of growing up all over the world, including Korea and Germany. These experiences provided unique perspectives and an appreciation for different cultures. Biology was my main interest in school – I was fascinated by how numerous cell types and signaling pathways performed in a spectacular orchestra to sustain “life.” As I started my journey to become a medical doctor, my mom was diagnosed with breast cancer. As my mom fought her cancer, it became abundantly clear that significant and urgent improvements were needed in the fight against cancer. As a result, my career goals became more focused – to define the biological underpinnings of cancer and to expand the arsenal of anti-cancer tools. At the University of Arizona, I completed my Bachelor of Science in General Biology followed by my Doctor of Philosophy in Cancer Biology. As a graduate student, I focused on examining cancer-specific protein-protein interactions and optimizing novel therapies to target breast cancer cells. After graduate school, I moved to the Fox Chase Cancer Center in Philadelphia, PA. As a post-doctoral fellow, this was my introduction to ovarian cancer. I quickly realized a significant gap existed in scientific and clinical ovarian cancer knowledge. I also recognized that achieving this goal required a cutting-edge basic science research program integrated with a robust clinical practice. The University of Colorado stood out as an institute that met this requirement and provided a path to achieving my goal. Since joining the University of Colorado, I have worked tirelessly to build a team of clinical and research collaborators who share my passion for eradicating ovarian cancer. The Gynecologic Oncology Research Program at the University of Colorado is supported by the Divisions of Reproductive Science and Gynecologic Oncology, generous and motivated philanthropists, and competitive research grants, including the Ovarian Cancer Research Alliance (OCRA) Collaborative Research Development Grant. The Gynecologic Oncology Research Program has three main research goals: 1) To overcome therapy-resistant ovarian cancer, 2) To define the biological underpinnings of ovarian cancer, and 3) To develop strategies to prevent ovarian cancer. We actively address the research goals through several highly collaborative research projects. Since November 2016, the University of Colorado Ovarian Cancer Research Group has developed a pipeline to assess ovarian cancer tumor composition and transcriptional profiles longitudinally. The research group, funded by the OCRA Collaborative Research Development Grant, consists of cancer biologists (Drs. Bitler, Sikora, and Richer), a computer scientist (Dr. Clauset), a gynecologic oncologist (Dr. Behbakht), a pathologist (Dr. Wolsky), and an immunologist (Dr. Jordan). We appreciate that improving ovarian outcomes will require the work of multi-disciplinary teams. The OCRA award will provide pivotal funding to expand our pipeline and empirically define several factors’ contribution in driving therapy response. Our vision is to use cutting-edge technology with machine learning in a clinically meaningful timeframe to predict disease recurrence and inform clinical decisions.